var data={"title":"Hydroxychloroquine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hydroxychloroquine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6342?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">see &quot;Hydroxychloroquine: Drug information&quot;</a> and <a href=\"topic.htm?path=hydroxychloroquine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hydroxychloroquine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180857\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Plaquenil</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180858\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Plaquenil</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047734\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antimalarial Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antirheumatic, Disease Modifying</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047727\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">see &quot;Hydroxychloroquine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> All doses below expressed as hydroxychloroquine sulfate. Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base and 250 mg chloroquine phosphate. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malaria:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chemoprophylaxis:</i> Infants, Children, and Adolescents: Oral: 6.5 mg/kg hydroxychloroquine sulfate once weekly on the same day each week; maximum dose: 400 mg/dose hydroxychloroquine sulfate; begin 1 to 2 weeks before exposure; continue for at least 4 weeks after leaving endemic area (CDC 2016). If the initiation of chemoprophylaxis is delayed (ie, 2 weeks of therapy not completed prior to the exposure), the manufacturer recommends initiating therapy by doubling the initial dose (13 mg/kg of hydroxychloroquine sulfate) and administering in 2 divided doses 6 hours apart; maximum single dose: 400 mg/dose hydroxychloroquine sulfate; continue for 8 weeks after leaving endemic area. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment; acute attack; uncomplicated:</i> Infants, Children, and Adolescents: Oral: Initial: 13 mg/kg/dose hydroxychloroquine sulfate (maximum initial dose: 800 mg/dose hydroxychloroquine sulfate); followed by 6.5 mg/kg hydroxychloroquine sulfate at 6, 24, and 48 hours after initial dose; maximum dose: 400 mg/dose hydroxychloroquine sulfate (CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>JRA or SLE:</b> 3 to 5 mg/kg/day divided 1 to 2 times/day to a maximum of 400 mg/day; not to exceed 7 mg/kg/day </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malaria, chemoprophylaxis:</b> Oral: 400 mg weekly on same day each week; begin 2 weeks before exposure; continue for 4 weeks (per CDC guidelines) after leaving endemic area; if suppressive therapy is not begun prior to the exposure, double the initial dose and give in 2 doses, 6 hours apart and continue treatment for 8 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malaria, acute attack:</b> Oral: 800 mg initially, followed by 400 mg at 6, 24, and 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis:</b> Oral: Initial: 400 to 600 mg daily taken with food or milk; increase dose gradually until optimum response level is reached; usually after 4 to 12 weeks dose should be reduced by 1/2 to a maintenance dose of 200 to 400 mg daily in 1 to 2 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lupus erythematosus:</b> Oral: 400 mg every day or twice daily for several weeks-months depending on response; 200 to 400 mg daily in 1 to 2 divided doses for prolonged maintenance therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180836\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plaquenil: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plaquenil: 200 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180822\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25226258\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047737\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Suppression or treatment of acute attacks of malaria (FDA approved in pediatric patients [age not specified] and adults); treatment of systemic lupus erythematosus (SLE) (FDA approved in adults) and acute or chronic rheumatoid arthritis (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180902\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hydroxychloroquine may be confused with hydrocortisone, hydroxyurea</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plaquenil may be confused with Platinol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180900\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Ataxia, dizziness, emotional disturbance, emotional lability, headache, irritability, lassitude, nerve deafness, nervousness, nightmares, psychosis, seizure, suicidal tendencies, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acute generalized exanthematous pustulosis, alopecia, bleaching of hair, bullous rash, dyschromia (skin and mucosal; black-blue color), erythema (annulare centrifugum), erythema multiforme, exacerbation of psoriasis (nonlight sensitive), exfoliative dermatitis, lichenoid eruption, maculopapular rash, morbilliform rash, pruritus, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Exacerbation of porphyria, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, diarrhea, nausea, stomach cramps, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, aplastic anemia, hemolysis (in patients with glucose-6-phosphate deficiency), leukopenia, purpuric rash, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Acute hepatic failure (rare), hepatic insufficiency (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Myopathy (including palsy or neuromyopathy, leading to progressive weakness and atrophy of proximal muscle groups; may be associated with mild sensory changes, loss of deep tendon reflexes, and abnormal nerve conduction)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Accommodation disturbance, corneal changes (transient edema, punctate to lineal opacities, decreased sensitivity, deposits, visual disturbances, blurred vision, photophobia [reversible on discontinuation]), decreased visual acuity, macular edema, nystagmus, optic disk disorder (pallor/atrophy), retinal pigment changes, retinal vascular disease (attenuation of arterioles), retinitis pigmentosa, retinopathy (early changes reversible [may progress despite discontinuation if advanced]), scotoma, vision color changes, visual field defect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports (Limited to important or life-threatening): Cardiomyopathy, epithelial keratopathy (Dosso 2007), hypoglycemia (Cansu 2008; Un&uuml;bol 2011), macular degeneration, maculopathy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180842\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to hydroxychloroquine, 4-aminoquinoline derivatives, or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Preexisting retinopathy; use in children &lt;6 years or weighing &lt;35 kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180826\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Cardiomyopathy resulting in cardiac failure, sometimes fatal, has been reported (symptoms may present as atrioventricular block, pulmonary hypertension, sick sinus syndrome, or as cardiac complications), and may appear during acute or chronic therapy. Monitor for signs/symptoms of cardiac compromise; discontinue treatment promptly if signs and symptoms of cardiomyopathy occur. In a scientific statement from the American Heart Association, hydroxychloroquine has been determined to be an agent that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]). Consider chronic toxicity if conduction disorders (eg, bundle branch block, atrioventricular heart block) as well as biventricular hypertrophy are diagnosed. May also be associated with QT interval prolongation; ventricular arrhythmia and torsades de pointes have been reported (avoid concurrent use of other medications which may prolong the QT interval).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic effects: Skin reactions to hydroxychloroquine may occur; use with caution in patients on concomitant medications with a propensity to cause dermatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Bone marrow suppression (eg, agranulocytosis, anemia, aplastic anemia, leukopenia, thrombocytopenia) have been reported; periodically monitor CBC during prolonged therapy. Discontinue treatment if signs/symptoms of severe blood disorder not attributable to the underlying disease occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoglycemia: Severe hypoglycemia, including life-threatening loss of consciousness, has been reported in patients with and without concomitant use of antidiabetic agents. Advise patients of risk of hypoglycemia and associated signs/symptoms; discontinue use in patients who develop severe hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuromuscular effects: Proximal myopathy or neuromyopathy, leading to progressive weakness, proximal muscle atrophy, depressed tendon reflexes, and abnormal nerve conduction may occur, especially with long-term therapy. Curvilinear bodies and muscle fiber atrophy with vacuolar changes have been noted on muscle or nerve biopsy. Muscle strength (especially proximal muscles) and reflexes should be assessed periodically during long term therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric effects: Suicidal behavior has been reported rarely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Retinal toxicity: Retinal toxicity, potentially causing irreversible retinopathy, is predominantly associated with high daily doses and a duration of &gt;5 years of use of chloroquine or hydroxychloroquine in the treatment of rheumatic diseases. Other major risk factors include concurrent tamoxifen use, renal impairment, lower body weight, and the presence of macular disease. Daily hydroxychloroquine (base) doses &gt;5 mg/kg actual body weight were associated with an ~10% risk of retinal toxicity within 10 years of treatment and an almost 40% risk after 20 years of therapy. Risk is most accurately assessed on the basis of duration of use relative to daily dose/body weight (Marmor [AAO 2016]; Melles 2014). Based on these risks, the American Academy of Ophthalmology (AAO) recommends not exceeding a daily hydroxychloroquine dosage of 5 mg/kg using <b>actual </b>body weight. Previous recommendations to use ideal body weight are no longer advised; very thin patients in particular were at increased risk for retinal toxicity using this practice. Current AAO guidelines do not specifically address dosing in obese patients. AAO also recommends baseline screening for retinal toxicity and annual screening beginning after 5 years of use (or sooner if major risk factors are present) (Marmor [AAO 2016]). If ocular toxicity is suspected, discontinue and monitor closely; retinal changes and visual disturbances may progress after discontinuation. A baseline ocular exam is recommended within the first year of initiating hydroxychloroquine treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; G6PD deficiency: Although the manufacturer's labeling recommends hydroxychloroquine be used with caution in patients with G6PD deficiency due to a potential for hemolytic anemia, there is limited data to support this risk. Many experts consider hydroxychloroquine, when given in usual therapeutic doses to WHO Class II and III G6PD deficient patients, to probably be safe (Cappellini 2008; Glader 2017; Luzzatto 2016; Youngster 2010). Safety in Class I G6PD deficiency (ie, severe form of the deficiency associated with chronic hemolytic anemia) is generally unknown (Glader 2017). In a retrospective chart review, no incidence of hemolytic anemia was found among the 11 patients identified with G6PD deficiency receiving hydroxychloroquine therapy, despite &gt;700 months of exposure (all patients were African-American and located in the US) (Mohammad 2017). In addition, the ACR Rheumatology guidelines do not mention the need to evaluate G6PD levels prior to initiation of therapy (Singh 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disorders: Use with caution in patients with gastrointestinal disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, alcoholism, or concurrent therapy with hepatotoxic agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Porphyria: Use with extreme caution in patients with porphyria; may exacerbate or precipitate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psoriasis: Use with extreme caution in patients with psoriasis; may exacerbate or precipitate disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Pediatric patients have an increased sensitivity to aminoquinolones. Safety and efficacy have not been established for chronic use in children for juvenile idiopathic arthritis or for systemic lupus erythematosus.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299491\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180831\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13366&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anthelmintics: Aminoquinolines (Antimalarial) may decrease the serum concentration of Anthelmintics. <b> Exceptions: </b>Niclosamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Aminoquinolines (Antimalarial) may decrease the metabolism of Beta-Blockers. <b> Exceptions: </b>Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol; Sotalol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Aminoquinolines (Antimalarial) may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: Aminoquinolines (Antimalarial) may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of Aminoquinolines (Antimalarial).  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial when possible.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): Hydroxychloroquine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): Hydroxychloroquine may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: May enhance the adverse/toxic effect of Hydroxychloroquine. Specifically, concomitant use of tamoxifen and hydroxychloroquine may increase the risk of retinal toxicity.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5265901\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Hydroxychloroquine can be detected in the cord blood at delivery in concentrations similar to those in the maternal serum (Costedoat-Chalumeau 2002). In animal reproduction studies with chloroquine, accumulation in fetal ocular tissues was observed and remained for several months following drug elimination from the rest of the body. Based on available human data, an increased risk of fetal ocular toxicity has not been observed following maternal use of hydroxychloroquine, but additional studies are needed to confirm (Osadchy 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Maternal lupus is associated with adverse maternal and fetal events; however, pregnancy outcomes may be improved if conception does not occur until the disease has been inactive for &ge;6 months. Hydroxychloroquine is one of the medications recommended for the management of lupus and lupus nephritis in pregnant women. If pregnancy is detected during therapy, it should not be stopped (could precipitate a flare in maternal disease and exposure to the fetus will still continue for 6 to 8 weeks due to tissue binding) (Baer 2011; Bertsias 2012; Hahn 2012; Levy 2001). Maternal use of hydroxychloroquine may also decrease the incidence of cardiac malformations associated with neonatal lupus (Izmirly 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Malaria infection in pregnant women may be more severe than in nonpregnant women and has a high risk of maternal and perinatal morbidity and mortality. Therefore, pregnant women and women who are likely to become pregnant are advised to avoid travel to malaria-risk areas. Hydroxychloroquine is recommended as an alternative treatment of pregnant women for uncomplicated malaria in chloroquine-sensitive regions (refer to current guidelines) (CDC 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women exposed to hydroxychloroquine for the treatment of rheumatoid arthritis or systemic lupus erythematosus during pregnancy may be enrolled in the Organization of Teratology Information Specialists (OTIS) Autoimmune Diseases Study pregnancy registry (877-311-8972).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047733\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Ophthalmologic examination at baseline and every 3 months with prolonged therapy (including visual acuity, slit-lamp, fundoscopic, and visual field exam), CBC with differential and platelet count; check for muscular weakness with prolonged therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180825\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with digestive vacuole function within sensitive malarial parasites by increasing the pH and interfering with lysosomal degradation of hemoglobin; inhibits locomotion of neutrophils and chemotaxis of eosinophils; impairs complement-dependent antigen-antibody reactions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180841\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Rheumatic disease: May require several weeks to respond </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Incomplete and variable (~70% [range: 25 to 100%]) (Tett 1993) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~40%, primarily albumin (Tett 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; metabolites include bidesethylchloroquine, desethylhydroxychloroquine, and desethylchloroquine (McChesney 1966)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~40 days (Tett 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (15% to 25% [Tett 1993]; as metabolites and unchanged drug [up to 60%, McChesney 1966]); may be enhanced by urinary acidification</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180840\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 25 mg/mL hydroxychloroquine sulfate oral suspension may be made with tablets. With a towel moistened with alcohol, remove the coating from fifteen 200 mg hydroxychloroquine sulfate tablets. Crush tablets in a mortar and reduce to a fine powder. Add 15 mL of Ora-Plus and mix to a uniform paste; add an additional 45 mL of vehicle and mix until uniform. Mix while adding sterile water for irrigation in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with sterile water, and add sufficient quantity of sterile water to make 120 mL. Label &quot;shake well&quot;. A 30-day expiration date is recommended, although stability testing has not been performed.</p>\n    <div class=\"reference\">Pesko LJ, &quot;Compounding: Hydroxychloroquine,&quot; <i>Am Druggist</i>, 1993, 207(4):57.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180844\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Hydroxychloroquine Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $408.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Plaquenil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $765.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180846\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Advaquenil (JO);</li>\n      <li>Arthroquin (IN);</li>\n      <li>Axokine (AR);</li>\n      <li>Chloguin (TW);</li>\n      <li>Diclor (IN);</li>\n      <li>Dimard (CO, EC);</li>\n      <li>Dolquine (ES, LB);</li>\n      <li>Duloc (KR);</li>\n      <li>Duroc (KR);</li>\n      <li>Ercoquin (DK);</li>\n      <li>Evoquin (AR, UY);</li>\n      <li>Fen Le (CN);</li>\n      <li>Geniquin (TW);</li>\n      <li>Haloxin (SG);</li>\n      <li>HCQS (IN, PE, TH);</li>\n      <li>Hydroquin (TH);</li>\n      <li>Hydroquine (TW);</li>\n      <li>Hyquin (BD, LK);</li>\n      <li>Ilinol (CL);</li>\n      <li>Immard (UA);</li>\n      <li>Metirel (UY);</li>\n      <li>Oxcq (LK);</li>\n      <li>Oxiklorin (FI, KR);</li>\n      <li>Plakvenil (UA);</li>\n      <li>Planil (BD);</li>\n      <li>Plaquenil (CN, CR, CY, DO, GT, IS, JP, KW, LT, LU, LV, MX, NI, PA, QA, RO, SA, SG, SV, VN);</li>\n      <li>Plaquenil Sulfate (AR, AU, BB, BE, BF, BG, BJ, BM, BS, BZ, CH, CI, CZ, DK, EE, ET, FR, GH, GM, GN, GR, GY, HK, HN, IE, IL, IT, JM, KE, LR, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, PH, RU, SC, SD, SE, SK, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Plaquinol (BR, CL, CO, EC, PE, PT, PY, VE);</li>\n      <li>Quensyl (DE);</li>\n      <li>Quinoric (MT);</li>\n      <li>Reconil (BD);</li>\n      <li>Reuquinol (BR);</li>\n      <li>Roquin (BD);</li>\n      <li>Supretic (PY);</li>\n      <li>Winflam (LK);</li>\n      <li>Yuma (KR);</li>\n      <li>Zyq (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Baer AN, Witter FR, and Petri M, &quot;Lupus and Pregnancy,&quot; <i>Obstet Gynecol Surv</i>, 2011, 66(10):639-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/22112525/pubmed\" target=\"_blank\" id=\"22112525\">22112525</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bertsias GK, Tektonidou M, Amoura Z, et al, &quot;Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) Recommendations For the Management of Adult and Paediatric Lupus Nephritis,&quot; <i>Ann Rheum Dis</i>, 2012, 71(11):1771-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/22851469/pubmed\" target=\"_blank\" id=\"22851469\">22851469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. <i>Rheumatology (Oxford)</i>. 2008;47(3):378-379.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/18222983 /pubmed\" target=\"_blank\" id=\"18222983 \">18222983 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. <i>MMWR Recomm Rep</i>. 2013;62(RR-03):1-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/23535757 /pubmed\" target=\"_blank\" id=\"23535757 \">23535757 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). The Yellow Book: CDC Health information for international travel 2016. Found at: <a href=\"http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/malaria#4661\" target=\"_blank\">http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/malaria#4661</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costedoat-Chalumeau N, Amoura Z, Aymard G, et al, &quot;Evidence of Transplacental Passage of Hydroxychloroquine in Humans,&quot;<i> Arthritis Rheum</i>, 2002, 46(4):1123-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/11953993/pubmed\" target=\"_blank\" id=\"11953993\">11953993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Emery H, &ldquo;Clinical Aspects of Systemic Lupus Erythematosus in Childhood,&rdquo; <i>Pediatr Clin North Am</i>, 1986, 33(5):1177-90. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/3763254/pubmed\" target=\"_blank\" id=\"3763254\">3763254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giannini EH and Cawkwell GD, &ldquo;Drug Treatment in Children With Juvenile Rheumatoid Arthritis. Past, Present, and Future,&rdquo; <i>Pediatr Clin North Am</i>, 1995, 42(5):1099-125. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/7567188 /pubmed\" target=\"_blank\" id=\"7567188 \">7567188 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Guidelines for the Management of Rheumatoid Arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines,&rdquo; <i>Arthritis Rheum</i>, 1996, 39(5):713-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/8639167/pubmed\" target=\"_blank\" id=\"8639167\">8639167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hahn BH, McMahon MA, Wilkinson A, et al, &quot;American College of Rheumatology Guidelines For Screening, Treatment, and Management of Lupus Nephritis,&quot; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(6):797-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/22556106/pubmed\" target=\"_blank\" id=\"22556106\">22556106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al, &quot;Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody-Associated Cardiac Manifestations of Neonatal Lupus,&quot; <i>Circulation</i>, 2012, 126(1):76-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/22626746/pubmed\" target=\"_blank\" id=\"22626746\">22626746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones SK, &ldquo;Ocular Toxicity and Hydroxychloroquine: Guidelines for Screening,&rdquo; <i>Br J Derm</i>, 1999, 140(1):3-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/10215761/pubmed\" target=\"_blank\" id=\"10215761\">10215761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy RA, Vilela VS, Cataldo MJ, et al, &quot;Hydroxychloroquine (HCQ) in Lupus Pregnancy: Double-Blind and Placebo-Controlled Study,&quot; <i>Lupus</i>, 2001, 10(6):401-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/11434574/pubmed\" target=\"_blank\" id=\"11434574\">11434574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osadchy A, Ratnapalan T, and Koren G, &quot;Ocular Toxicity in Children Exposed <i>in utero</i> to Antimalarial Drugs: Review of the Literature,&quot; <i>J Rheumatol</i>, 2011, 38(12):2504-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/22002012/pubmed\" target=\"_blank\" id=\"22002012\">22002012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M, Brown ND, Chiang PK, et al, &quot;Hydroxychloroquine in Human Breast Milk,&quot; <i>Eur J Clin Pharmacol</i>, 1985, 28(3):357.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxychloroquine-pediatric-drug-information/abstract-text/4007043/pubmed\" target=\"_blank\" id=\"4007043\">4007043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plaquenil (hydrocholorquine) [prescribing information]. Bridgewater, NJ: Sanofi-aventis U.C. LLC; April 2012.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13366 Version 163.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F180857\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F180858\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047734\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047727\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F180836\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F180822\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25226258\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047737\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F180902\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F180900\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F180842\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F180826\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299491\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F180831\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5265901\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047733\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F180825\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F180841\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F180840\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F180844\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F180846\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13366|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">Hydroxychloroquine: Drug information</a></li><li><a href=\"topic.htm?path=hydroxychloroquine-patient-drug-information\" class=\"drug drug_patient\">Hydroxychloroquine: Patient drug information</a></li></ul></div></div>","javascript":null}